Comorbidity in patients with lymphoproliferative disorders: overview and own data

The problem of the influence of co-morbidity on the clinical course of the underlyingdisease, assessing the effectiveness of drug therapyand disease prognosis is actual for scientists invarious medical fields for more than 40 years.Based on their research, various indexes werecreated for evaluating co-morbidity. This articlepresents the results of the study of co-morbidityin patients with lymphoproliferative diseases. Twoscales were used for calculations: the CharlsonCo-morbidity Index (CCI) and the CumulativeIllness Rating Scale for Geriatrics (CIRS-G). FromJanuary 2018 to October 2019 we surveyed 127primary patients with lymphoproliferative diseasesaged from 19 to 95 years, the average age was 51.4 years. There were 100 males (78,74 %) and27 females (21,26 %). By the types of diseasesthe patients were distributed as follows: non-Hodgkin's lymphoma - 59 (of 46,46 %), Hodgkinlymphoma - 35 (27,56 %), multiple myeloma -20 (15,77 %), chronic lymphocytic leukemia - 7(5,51 %), and Waldenstrom's macroglobulinemia -3 (2,36 %), one patient each had hairy cell leukemia,T-cell leukemia of large granular lymphocytes, T-cellpro lymphocytic leukemia, that amounted to 0,78 %.The study found that overall co-morbidity wassignificant. On the first place cardiovascular diseasewas identified - 45,7 % of patients, on the secondplace were diseases of gastrointestinal tract - 42.5 % of patients, on the third place - diseasesof genitourinary system -24,4 % of patients.